What Happened

In 2024, Emilie and Justin Solomon traveled to Greece for IVF treatment after being quoted $40,000 for a single IVF cycle in their home state of Florida. Their trip, kept discreet from family and friends, included multiple visits to clinics in Athens, where comprehensive treatment cost roughly $12,000 excluding travel expenses. The couple’s journey exemplifies a growing trend: Americans crossing borders to obtain fertility care at a fraction of domestic prices.

This shift comes amid escalating treatment costs in the United States, where a study by Axene Health Partners and the Women’s Reproductive Health Foundation put the average IVF cycle cost above $29,000 in 2024—the equivalent of 35% of median annual household income. Additional services such as genetic testing, embryo storage, and prenatal care can drive total expenses beyond $54,000 per IVF-conceived birth.

Demand for IVF and other assisted reproductive technologies has resulted in more than 100,000 babies born via IVF in the U.S. during 2024—a record high according to the Society for Assisted Reproductive Technology. Nevertheless, infertility affects nearly 7 million Americans, with only about 24% of treatment needs currently met due to financial barriers and inconsistent insurance mandates.

Key Facts

Data indicate substantial disparities in IVF affordability:

• An IVF cycle in Greece generally costs between $3,000 and $4,000 for procedures using a patient’s own eggs, excluding medication.
• The Solomons’ two trips to Greece included ovulation stimulation, egg retrieval, fertilization, embryo transfer, and storage for approximately $12,000 total.
• U.S. IVF medication costs have surged by nearly 90% since 2014, partially offset by government discount programs like TrumpRx, which may save patients up to $2,200 per cycle.
• CNY Fertility, a U.S.-based provider, offers cycles around $8,000 but still sees many patients traveling out of state seeking affordable care.
• American patient visits to European fertility clinics increased by more than 37% in 2025, according to the European Fertility Society.
• Legal differences in countries like Greece affect embryo storage duration, donor anonymity, and eligibility criteria for procedures such as surrogacy.
• Nearly two to three IVF cycles are typically required for a successful live birth, compounding financial and emotional stresses.

What This Means

The steep and rising cost of IVF treatments in the U.S., compounded by inconsistent insurance coverage, is creating a significant access barrier for many hopeful parents. American patients are increasingly compelled to seek fertility care abroad, where procedures are more affordable and wait times shorter. This trend highlights systemic challenges in the U.S. healthcare system related to coverage of reproductive health services.

Traveling overseas for IVF introduces new complexities, including navigating foreign regulatory requirements, managing transportation of medications, and addressing continuity of care between countries. Patients may face difficulties in transferring medical records or understanding diagnoses obtained abroad. While international clinics provide cost relief, these hurdles necessitate cautious decision-making and often, considerable logistical effort.

Moreover, for some patients, fertility tourism can blend treatment with an emotionally supportive environment or vacation—potentially mitigating some psychological burdens associated with fertility procedures. However, economic disparities remain: traveling abroad is not a viable option for all, underscoring ongoing inequities in access to reproductive technologies.

Background

Infertility rates have been rising in the U.S., attributed to factors such as delayed childbearing and environmental influences like pollution. Despite this, insurance coverage for fertility treatments varies widely across states, with many plans excluding provisions for IVF or related reproductive services. This patchwork of policies contributes to the financial challenges faced by patients.

The current administration has proposed measures to improve employer-based fertility coverage, though these rules remain in development. Additionally, government initiatives have marginally lowered some medication costs, but these savings have not kept pace with the overall rise in IVF-related expenses.

Analysis

Experts such as Jakub Dejewski, chair of the European Fertility Society, note that American patients choose European clinics not only for affordability but also for quicker access and international patient support services these clinics provide. Penny Ampatzi, clinic director at Serum IVF in Athens, emphasizes that personalized care combined with reasonable costs attracts a growing number of foreign patients.

Within the U.S., William Kiltz of CNY Fertility describes the IVF market as emotionally charged, with prices often placing treatment out of reach for most except wealthier individuals. Providers aiming to reduce costs can sustain operations but often only at minimal profit margins, reflecting systemic inefficiencies.

Tarita Pakrashi, a reproductive specialist in Virginia, warns of the challenges patients face when pursuing overseas treatment—complex regulations, language barriers, and follow-up care issues can hinder successful outcomes and continuity.

What Comes Next

The U.S. government’s potential finalization of fertility coverage rules could improve financial accessibility for some patients, but no final regulatory changes have yet been enacted. Researchers and advocacy groups continue monitoring IVF costs and treatment accessibility, while clinics domestically and abroad adjust to shifting patient demands.

Read more Health & Public Health stories on Goka World News.

The post Rising U.S. IVF Costs Drive Patients to Seek Treatment Abroad appeared first on Goka World News.

What Happened

On a summer morning two years ago, Meredith Melville, a 73-year-old retired teacher, was struck by a car while crossing a street in Oakland, California. Despite using a crosswalk, she was hit by a Toyota sedan driven by a motorist who did not observe her in time. Melville sustained multiple fractures, including a replaced right hip and repaired broken elbow, followed by a long recovery involving hospitalization and rehabilitation. Her personal story illustrates the broader national trend: in 2023, nearly 8,200 pedestrians aged 65 and older were injured in traffic crashes, and over 1,500 in this age group died as a result.

Although older pedestrians are not injured more frequently than younger people, their fatality rate is significantly higher and has remained stubbornly flat for nearly two decades, according to data from the Insurance Institute for Highway Safety (IIHS).

Key Facts

The 2023 NHTSA data reported an estimated 8,200 injuries and more than 1,500 deaths among pedestrians aged 65 and older. The Insurance Institute for Highway Safety showed that from 2008 through 2024, pedestrian fatalities in people aged 70 and older have stayed consistently higher than average and have not declined. Researchers attribute this to several factors:

• Older adults often move more slowly through intersections and have impaired hearing or vision, limiting their ability to notice traffic signals or oncoming vehicles.
• Reaction times decline with age, reducing the capacity to avoid vehicles that are speeding, turning, or disobeying signals.
• Physical frailty, including loss of muscle mass and more fragile bones, leads to worse injury outcomes, such as hip fractures that carry significantly higher morbidity in older adults.
• The National Health and Aging Trends Study noted an increase in older adults walking for exercise—from 60% in 2011 to 65% in 2023—potentially increasing their exposure as pedestrians.
• Changes in vehicle types, with the rise of larger SUVs and trucks that have tall hoods and larger blind spots, have increased the danger posed to pedestrians.
• The rapid growth in use of electric bikes and motor-assisted two-wheeled vehicles, which can reach higher speeds, has sparked concerns over increased injury risks though national data remain incomplete.
• Alcohol plays a role, with about one-third of adult pedestrians killed at night having blood alcohol levels above legal limits, and 20% during the day.

What This Means

The higher fatality risk for older pedestrians highlights the intersection of aging physiology, behavioral patterns, and traffic environment challenges. Older individuals’ slower movement and reduced sensory ability increase their vulnerability amid modern traffic conditions, particularly with the rise of larger vehicles and faster micromobility devices. The consequences of crashes among older pedestrians are more severe, demanding comprehensive approaches to pedestrian safety tailored to their needs.

This trend also reflects a growing public health challenge as more older adults engage in walking for exercise and daily activities, emphasizing the importance of adapting urban planning and traffic policies. Interventions such as improved street lighting, pedestrian islands, longer crossing times, and lowered speed limits can mitigate risk. Moreover, recognizing alcohol consumption among pedestrians as a contributing factor points to potential prevention strategies beyond focusing solely on impaired drivers.

Background

After decades of decline in pedestrian deaths across all age groups from 1975 until the mid-2000s, progress has plateaued for older adults. Public health strategies like Vision Zero have been adopted in hundreds of municipalities aiming to reduce traffic fatalities through safer street designs and traffic regulation, yet these solutions remain uneven and face challenges from changing traffic dynamics. Research suggests tailoring safety measures in neighborhoods with high densities of senior destinations such as hospitals and community centers could target resources effectively.

Analysis

Andrew Rundle, an epidemiologist at Columbia University, emphasizes the frailty and sensory decline that slow older pedestrians and impair their ability to react to traffic hazards. Charles DiMaggio, an injury epidemiologist at NYU Grossman School of Medicine, notes the stark difference in outcomes between younger and older adults suffering the same injuries, such as hip fractures, which can be life-altering or fatal in seniors.

Stephen Mooney of the University of Washington underscores the need for creating traffic systems that do not rely on pedestrians avoiding vehicles but instead prioritize safer environments for all ages and physical capabilities. Noah Miterko of PeopleforBikes calls for regulation of higher-speed electric bikes akin to motor vehicles, reflecting growing concerns about evolving mobility risks.

What Comes Next

Public health officials and researchers advocate expanding and accelerating implementation of traffic safety measures designed with older pedestrians in mind, including pedestrian-friendly street designs and signal timing adjustments. Some states and cities are beginning to regulate electric bikes more rigorously to address injury concerns. Ongoing monitoring of e-bike-related injuries and fatalities will inform future policies and prevention efforts.

Read more Health & Public Health stories on Goka World News.

The post Why Older Pedestrians Face Higher Fatality Rates in Crashes appeared first on Goka World News.

What Happened

Céline Gounder, the editor-at-large for public health at KFF Health News, appeared on CBS News 24/7’s “Mornings” on August 26 to discuss recent fatal cases of measles, providing fact-checking of vaccine-related claims made by Centers for Medicare & Medicaid Services Administrator Mehmet Oz in an earlier CBS interview. Around the same week, Gounder also appeared on “The Takeout With Major Garrett” on August 24 to talk about the summer’s food recalls.

Meanwhile, KFF’s chief Washington correspondent Julie Rovner addressed kindergarten vaccination rates during her August 25 appearance on WNYC’s “The Brian Lehrer Show.” Additionally, contributor Mark Kreidler spoke on KVPR’s “Central Valley Daily” on August 24 about the application of artificial intelligence to Medicaid reenrollment efforts, highlighting both the potential benefits and concerns.

Senior correspondent Julie Appleby discussed the current state of the Affordable Care Act on Vox’s “Today, Explained” podcast on August 24, situating health policy within an electoral context. Further, KFF’s Georgia correspondent Briah Lumpkins spoke about the significant role healthcare policy will play in the upcoming elections on WUGA’s “The Georgia Health Report” on August 21.

Key Facts

KFF Health News, an independent source of health policy research and journalism, has engaged its reporters and contributors in interviews across prominent platforms to discuss the following key topics: fatal measles incidence within the U.S., vaccination coverage among kindergarteners, notable food product recalls during the summer months, and the use of AI technology in public healthcare enrollment systems.

Precise statistics regarding measles fatalities, vaccination rates, or food recall volumes were not detailed in these appearances but were addressed as part of ongoing public health concerns. KFF Health News is one of the U.S.’s leading independent health policy newsrooms, providing in-depth reporting and analysis ahead of the 2024 midterms.

What This Means

The media engagement by KFF Health News journalists highlights the interconnectedness of public health challenges and policy as voters prepare for the midterm elections. Coverage of fatal measles cases underscores the continued risks posed by vaccine-preventable diseases amid fluctuating vaccination rates. Discussions on kindergarten vaccine uptake stress the importance of early childhood immunization in preventing outbreaks.

Food recalls remain a critical public safety issue, reminding consumers and health officials of the ongoing need for vigilance in food supply monitoring. The conversations about Medicaid reenrollment processes, particularly the integration of artificial intelligence, highlight both advancements and concerns in healthcare administration affecting millions of Americans.

Finally, the reaffirmed attention on the Affordable Care Act and healthcare policy in key states reflects the enduring political significance of health coverage in U.S. elections. Collectively, these discussions help inform the public about health system challenges, resource allocation, and the impact electoral choices may have on community well-being.

Background

Measles elimination was achieved in the U.S. in 2000 due to widespread vaccination, but outbreaks have recurred in recent years linked to vaccine hesitancy and gaps in coverage. The Affordable Care Act, passed in 2010, remains a central and contested piece of health legislation, expanding coverage for millions but facing political and legal challenges.

Food recalls often result from contamination or labeling errors and can prompt severe health risks, necessitating public communication. Medicaid, the nation’s largest health insurer, is undergoing modernization in enrollment and re-enrollment technologies to improve access and efficiency.

Read more Health & Public Health stories on Goka World News.

The post Journalists Highlight Measles, Vaccination, Food Recalls, and Health Policy Ahead of Midterms appeared first on Goka World News.

What Happened

In 2025, Secretary Kennedy and former President Donald Trump announced a series of voluntary agreements with food manufacturers, drugmakers, and health insurers aimed at improving American health outcomes without imposing federal regulations. High-profile efforts included a pledge by some companies to phase out nine synthetic petroleum-based dyes from foods and medications and commitments from major insurers to reduce prior authorization requirements, a practice many view as a barrier to timely care.

Nearly two years after these announcements, progress remains uneven. While federal officials claim some companies have voluntarily removed synthetic dyes from products served in schools, most dyes targeted remain in use, and broader industry adoption lags. Similarly, insurers have only achieved an approximately 11% reduction in prior authorization usage—far short of the pledged 80% target by January 2026. Furthermore, promised public dashboards to monitor insurer progress have not materialized.

Key Facts

The initial agreement to remove synthetic dyes involved 27 companies as of December 2025. However, less than 30% of those companies had met their voluntary targets by mid-2026. Major food and beverage producers like Coca-Cola and Unilever have made no public commitments to eliminate these dyes. No pharmaceutical companies have announced plans to remove dyes from medications.

Regarding insurer reforms, the trade group America’s Health Insurance Plans (AHIP) reported an 11% reduction in prior authorization volume as of July 2026, despite earlier promises that 80% of insurers would implement such changes for 80% of covered conditions by January 2026. A 2025 American Medical Association survey of 1,000 practicing doctors found only one-third believed these voluntary pledges would yield meaningful results.

Additionally, the administration attempted to introduce nutrition content into medical licensing exams, although this was later clarified to be a misstatement, with no immediate changes implemented.

What This Means

These voluntary agreements illustrate the Trump administration’s strategy of favoring industry cooperation over formal federal regulation in health policy. While such deals can bypass lengthy regulatory processes and allow for speedier announcements of progress, the lack of enforcement mechanisms and transparency constrains their real-world impact. Consumers and patients may remain unaware that many of the announced commitments have not gone beyond preliminary promises, potentially fostering misplaced confidence in public health improvements.

The absence of clear, publicly accessible benchmarks or tracking tools impedes public accountability and oversight. This lack of transparency makes it difficult for policymakers and voters to assess whether the administration’s health initiatives are genuinely effective or primarily serve political messaging. The experience also highlights broader challenges of relying on voluntary industry actions in sectors where economic incentives may not align with public health goals.

For elected officials like Rep. Tom Barrett, the visibility of these agreements offers a political narrative to promote during election campaigns. However, the substantive gap between promotional claims and verifiable progress could become a point of scrutiny in assessing the administration’s legacy on health policy.

Background

Before these voluntary deals, federal efforts to regulate health-related industry practices—such as FDA interventions concerning food additives and government management of prior authorization protocols—have often encountered opposition from industry groups wary of regulatory burdens. The Trump administration’s approach fits within a broader Republican preference for deregulation and market-driven solutions over mandates. However, past voluntary initiatives, such as those during the Carter administration aimed at controlling hospital costs, have similarly faltered once political attention diminished.

What Remains Unclear

It is uncertain whether future regulatory steps will be taken to enforce these voluntary agreements or if formal rules will replace the current voluntary framework. The long-term impact of partial dye removal on public health, given the substitution with natural dyes that may carry their own risks, remains to be fully assessed. The ability of artificial intelligence pilots in prior authorization to improve patient care efficiency has yet to be demonstrated on a large scale.

What Comes Next

The Department of Health and Human Services and FDA have indicated timelines extending through the end of 2027 for full dye phaseout in products, particularly in foods served in schools. The administration also continues to pilot AI-based prior authorization programs for select Medicare procedures in six states, which will be evaluated for broader implementation. Meanwhile, public health advocates and watchdog groups continue to call for greater transparency and more enforceable measures.

Read more Health & Public Health stories on Goka World News.

The post Trump and Kennedy’s Voluntary Health Industry Agreements Face Implementation Challenges appeared first on Goka World News.

What Happened

Since the World Health Organization (WHO) declared the Ebola outbreak a public health emergency on May 17, 2022, health authorities have confirmed over 5,200 Ebola cases and more than 2,500 deaths in the Democratic Republic of Congo (DRC), primarily centered in the Ituri province. As of August 7, over 550 people remained in isolation with suspected or confirmed Ebola, according to the Congolese National Public Health Institute.

Neighboring Uganda reported 20 cases and two deaths but has not registered new infections since June 21. The Bundibugyo variant, responsible for this outbreak, is rare and currently lacks a licensed vaccine, contributing to a reported fatality rate of 44% among cases in Congo. Military conflicts in eastern Congo have complicated response efforts, delaying containment measures.

Key Facts

The current outbreak is the third occurrence of the Bundibugyo strain in central Africa. The CDC data form the basis for confirmed case counts and fatalities. The WHO and Africa Centres for Disease Control and Prevention (Africa CDC) have launched a joint response plan announced June 5, requesting over $500 million in funding over six months to strengthen regional containment strategies, including enhancing cross-border communication.

Several organizations operate on the ground, including Congo’s National Institute for Biomedical Research, which conducts virus testing and genomic surveillance to track viral evolution and support vaccine development. Médecins Sans Frontières (Doctors Without Borders) deploys over 1,400 staff in Ituri province, delivering emergency medical aid and maintaining healthcare services. The International Medical Corps runs treatment and rapid response centers while emphasizing local health worker training to ensure sustainable outbreak management. Locally, the women-led nonprofit SOFEPADI targets protections for women, a group disproportionately affected by Ebola due to caregiving roles.

What This Means

The persistence of the Ebola outbreak in Congo highlights the ongoing challenges faced in controlling highly infectious diseases in conflict-affected regions with limited healthcare infrastructure. The absence of a vaccine for the Bundibugyo strain underscores the increased vulnerability of affected populations and the critical need for surveillance and supportive care to reduce mortality. Continued international funding and coordinated efforts from global and local organizations are essential to sustain response activities.

The emphasis on building local healthcare capacity through training by organizations like International Medical Corps suggests a strategic shift toward empowering communities for future outbreak preparedness. Addressing community mistrust and providing clear communication are vital for improving prevention adherence, especially in regions where misinformation may hamper containment efforts.

Moreover, attention to gender dynamics by groups like SOFEPADI reflects an understanding that protecting caregivers—mainly women—is crucial for preserving the social fabric and effective response, given their frontline role in households and healthcare environments during epidemics.

Background

The 2014–2016 West African Ebola outbreak, the deadliest on record, resulted in over 11,300 deaths and raised global awareness about the need for robust outbreak response and vaccine development. The Bundibugyo strain is less common and presents different public health challenges, including the current lack of a licensed vaccine. The ongoing instability and armed conflict in eastern Congo complicate access for medical teams and community health outreach.

What Comes Next

The WHO and Africa CDC continue to coordinate resource mobilization and cross-border surveillance under the “One Response” framework. Vaccine trials targeting the Bundibugyo strain are underway, although no approved vaccine exists yet. Health organizations plan to sustain and expand community education, treatment services, hygiene promotion, and healthcare workforce training to both control the present outbreak and strengthen long-term resilience.

Read more Health & Public Health stories on Goka World News.

The post Efforts Continue as Ebola Persists in Central Africa appeared first on Goka World News.

What Happened

On August 19, Céline Gounder, editor-at-large for public health at KFF Health News and a former melanoma patient, discussed Moderna’s new melanoma vaccine breakthrough on CBS News 24/7’s The Daily Report. This promising development represents a significant stride forward in cancer vaccine technology. Additionally, on August 14, KFF correspondent Renuka Rayasam appeared on WUGA’s The Georgia Health Report to report on hospitals adopting wristbands designed to reduce maternal deaths during childbirth. These wristbands serve as tools to monitor and improve maternal safety, reflecting hospitals’ efforts to combat the ongoing challenge of maternal mortality in the U.S.

Key Facts

Céline Gounder’s remarks on Moderna’s vaccine were grounded in her unique perspective as both a public health expert and melanoma survivor, providing a personal understanding alongside scientific insight. Renuka Rayasam’s reporting highlighted how hospitals’ use of wristbands has been recognized by health professionals as a practical, low-cost intervention to improve maternal care outcomes. While the exact statistical impact of the wristbands was not detailed in these reports, their adoption signals an institutional shift toward addressing maternal health risks more effectively. The journalists’ engagement across platforms like CBS News, NPR’s Stateside, and WUGA illustrates KFF Health News’ broad reach in public health journalism.

What This Means

The spotlight on Moderna’s melanoma vaccine breakthrough represents an important example of how vaccine technology is expanding beyond infectious diseases to target cancers, potentially transforming treatment paradigms and offering hope for improved survivorship. Public awareness raised by a knowledgeable figure such as Gounder may increase understanding and acceptance of new vaccine approaches.

Simultaneously, the introduction of wristbands in hospital settings to reduce maternal deaths underscores an ongoing effort to tackle a persistent public health issue in the United States. Maternal mortality rates remain higher than in many comparable countries, and simple interventions like wristbands to track patient information more effectively could provide critical safety improvements, potentially saving lives.

These journalistic efforts highlight the importance of clear, evidence-based communication in public health, helping bridge gaps between medical innovation, healthcare providers, and the public. They also underscore how innovations can span prevention, treatment, and safety monitoring—addressing health challenges on multiple fronts.

Background

Melanoma is a severe form of skin cancer with historically limited vaccine options. Moderna’s venture into melanoma vaccines builds on its success with mRNA vaccine technology during the COVID-19 pandemic, applying similar techniques to oncology. On the maternal health front, hospitals and public health officials have sought various interventions, from protocol standardization to technology adoption, in an effort to lower maternal mortality rates, which have been rising in the U.S. despite global downward trends.

Read more Health & Public Health stories on Goka World News.

The post Innovations in Vaccines and Maternal Health Highlighted by Journalists appeared first on Goka World News.

What Happened

Broadcast nationally each Sunday at 9 a.m. ET, CBS Sunday Morning’s August 23 episode focused on multiple domestic stories. The lead coverage detailed a surge in emergency room visits across the United States tied to tick bites, particularly from lone star ticks known to cause Alpha-gal syndrome—a meat allergy triggered by the tick bite. The story featured residents of Martha’s Vineyard, Massachusetts, examining efforts to combat this growing health concern.

Additional segments took viewers to Sandyston, New Jersey, to explore Ricky Boscarino’s Luna Parc—an artistic home and garden space with decades of eclectic sculptures and mosaics. The program also revisited the iconic 1958 Harlem photograph by Art Kane that captured jazz legends congregating on a New York City brownstone stoop. Correspondents spoke with Kane’s son and bassist Ron Carter about the image’s lasting cultural impact.

The episode included an arts segment about Robert Lang, an origami master and physicist who lost his home and art collection in the 2025 Altadena wildfire. Lang’s story highlights community efforts to restore his work. Other features included reflections on Casa Verdi, a Milan retirement home for musicians founded by composer Giuseppe Verdi, and a tribute to eight-year-old Fletcher Merkel, one of the young victims of a shooting at Annunciation Catholic Church in Minneapolis.

Key Facts

The program highlighted expert commentary on tick-borne diseases from Thomas Mather of the University of Rhode Island and Sam Telford III of Tufts University. Martha’s Vineyard medical professionals and community groups such as TickWiseMV and Tick Free Martha’s Vineyard contributed perspectives on prevention.

Ricky Boscarino’s Luna Parc is an 8.5-acre site featuring over 35 years of artistic installations, located in Sandyston, New Jersey. The Art Kane photograph was shot at 126th Street, Harlem, NYC, with the original published in Esquire magazine. Bassist Ron Carter, who played with many musicians in the photo, shared insights in the program.

Robert Lang’s origami pieces were part of the 2025 wildfire destruction; his work, “Vertical Pond III,” was previously displayed in California’s Descanso Gardens. The Casa Verdi facility in Milan was spotlighted for its unique role supporting retired professional musicians. Fletcher Merkel was remembered including a look at his preserved bedroom, following the August 2025 Minneapolis shooting.

What This Means

The rising number of tick bite cases and incidents of Alpha-gal syndrome underscore increasing public health challenges tied to environmental changes and tick population growth. This health threat has serious consequences for those affected, as it can indefinitely alter dietary habits. Such coverage raises awareness for preventive measures among communities at risk.

Highlighting iconic cultural contributions through art and music educates audiences about the legacies that enrich American history and identity. Revisiting stories of tragedy, such as the Minneapolis shooting victims, humanizes national safety issues and honors those lost, fostering community reflection about gun violence.

These varied stories together emphasize the importance of public health vigilance, artistic heritage, and social remembrance in shaping informed and empathetic communities.

Background

Alpha-gal syndrome has emerged as a notable tick-borne illness in recent years and causes a severe allergy to red meat. Lone star ticks, primarily found in the Eastern and Southern U.S., are the main vectors. Cases have escalated significantly, prompting medical and public outreach on prevention.

Ricky Boscarino’s Luna Parc has operated for more than three decades as a private art environment inviting visitors to engage with unconventional art installations. The Harlem jazz photo is widely regarded as one of the most significant group portraits in music history, symbolizing a golden era of jazz.

Robert Lang’s story connects scientific innovation and traditional art, representing resilience after wildfire destruction. Casa Verdi’s founding by Giuseppe Verdi reflects historical efforts to care for artists beyond their working years.

What Comes Next

CBS Sunday Morning continues to air weekly with a combination of in-depth feature stories, cultural retrospectives, and human-interest narratives. Viewers can stream episodes on the CBS News app or watch full episodes on-demand through multiple platforms. The network has announced upcoming live events starting September 28 at New York’s 92nd Street Y, featuring conversations with prominent figures in arts and culture.

Read more Health & Public Health stories on Goka World News.

The post CBS Sunday Morning Highlights Tick Bite Surge and Cultural Stories appeared first on Goka World News.

What Happened

In December 2024, Governor Jeff Landry, a conservative Republican, named Evelyn Griffin as Louisiana’s surgeon general. Griffin, a longtime obstetrician-gynecologist without formal infectious disease or public health training, had previously testified against adding COVID-19 vaccines to the state’s school immunization schedule. This marked a significant shift in Louisiana’s public health leadership, given the state’s historically poor health outcomes. Griffin also serves on the federal Advisory Committee on Immunization Practices (ACIP), where she voted to limit COVID-19 vaccine access and recommended ending universal newborn hepatitis B immunizations—actions that were legally challenged.

Since assuming office, Griffin has advocated for “dramatic transformational change” in healthcare, focusing on women’s health, rural health, and addressing root causes of disease. She has appeared at alternative health gatherings promoting lifestyle and faith-based wellness and has publicly questioned vaccine mandates and questioned established public health guidance. Despite her ambitions, Griffin has yet to enact major policy changes, encountering legislative resistance on vaccine-related bills.

Key Facts

Louisiana has the nation’s worst health outcomes, grappling with chronic disease burdens and social determinants of health. By December 2021, the state recorded over 14,000 COVID-19 deaths, including a surge that claimed six pregnant women within two months. Griffin joined ACIP in September 2024 under Health Secretary Robert F. Kennedy Jr., known for his controversial vaccine skepticism. At ACIP meetings, Griffin expressed uncertainty about vaccine safety in relation to autism, echoing disputed claims. She also supported increased access to ivermectin for COVID-19, a treatment shown ineffective by numerous studies. Her stance has sparked warnings from public health experts about potential risks to disease control.

Griffin’s background includes work within Louisiana’s largest health system, Ochsner Health, before resigning amid disputes over pandemic responses. She and her husband, vascular surgeon Joseph Griffin, are active in alternative health circles and state-level conservative health movements aligned with vaccine skepticism. Griffin publicly supports recent bans on government health mandates and gender-transition treatments for minors.

What This Means

Griffin’s leadership illustrates a growing challenge to traditional public health practices in Louisiana and potentially nationwide. Her focus on prevention over treatment aligns with broader calls for addressing lifestyle and social factors influencing health but is layered with skepticism toward vaccination and established infectious disease controls. This mix creates tension in a state vulnerable to outbreaks and chronic health crises.

Her position enables significant influence over state policy and public opinion, which could reshape how Louisiana manages disease prevention and public health interventions. However, public health experts warn that restricting vaccine access and government health powers could increase risks of disease outbreaks and complicate responses to future pandemics. While prevention efforts can improve long-term health outcomes, undermining vaccination and other proven strategies may have immediate adverse effects, particularly in a state where infectious diseases continue to cause substantial morbidity and mortality.

Griffin’s background and alliances signal the entrenchment of alternative health concepts and political ideology in public health leadership, complicating efforts to rely on consensus science and evidence-based policies. Her reliance on faith and lifestyle as cornerstones of health, alongside controversial figures known for fringe medical views, reflects a cultural shift affecting policy debates in health care and disease control.

Background

Griffin’s public health views crystallized during the COVID-19 pandemic when she opposed mandates on masking, vaccines, and treatments promoted by mainstream medical authorities. Her testimony against requiring COVID-19 vaccines for schoolchildren in 2021 cited historical references to vaccine-related drug tragedies and medical ethics trials, arguments which helped sway the state away from adopting such a mandate.

The state’s resistance to vaccine mandates and Griffin’s advocacy have parallels with national movements opposing government public health interventions during the pandemic. Louisiana’s legislative attempts, influenced in part by Griffin and aligned groups, reflect a broader trend to curtail public health authority, with potential implications for disease control and health equity.

Analysis

Experts like Georges Benjamin, chief executive of the American Public Health Association, describe Griffin’s views as “very dangerous,” highlighting concerns over potential increases in preventable illness and death if vaccination and public health authorities are weakened. Conversely, some colleagues, including Kirk Milhoan, chair of the federal vaccine panel, defend Griffin’s commitment to caring for Louisiana’s population, noting her political inexperience but endorsing her readiness to promote health reforms.

What Remains Unclear

The effectiveness and consequences of Griffin’s alternative health policies remain uncertain. It is unclear how much her preventive health focus will reduce chronic diseases or how public health authorities will manage infectious disease outbreaks under her influence. Regulatory agencies have not yet determined the future of vaccine mandates and public health powers in Louisiana amid ongoing legislative debates.

What Comes Next

Griffin has testified recently on bills related to restricting vaccine mandates and expanding alternative treatments though these have faced legislative rejection. Her role as surgeon general primarily serves as an advisory position, meaning her influence will largely depend on collaboration with the governor, state health secretary, and lawmakers. Further developments in state health policies will indicate the extent of her impact on Louisiana’s health landscape.

Read more Health & Public Health stories on Goka World News.

The post Louisiana’s New Surgeon General Seeks Public Health Overhaul appeared first on Goka World News.

What Happened

On August 10, 2025, President Trump signed an executive order directing the Department of Health and Human Services (HHS) to limit childhood vaccine recommendations. Although the order does not explicitly mention autism, the president publicly reiterated longstanding but discredited claims that vaccines contribute to the rising number of autism diagnoses. The directive came amid growing political debates ahead of the midterm elections and just after confirmation of key health agency leaders, including new CDC director Erica Schwartz.

Meanwhile, Kennedy, appointed as health secretary, has overseen a multi-million-dollar research project aimed at identifying causes of autism, a strategy criticized for its secrecy and lack of transparency. Despite more than a year of effort and repeated promises by Kennedy to deliver answers, no conclusive evidence linking vaccines to autism has surfaced. Public health officials and autism researchers have largely been excluded from the process.

Key Facts

Autism diagnoses in the United States have increased approximately fivefold over recent decades, a trend widely attributed by experts to expanded screening, broader diagnostic criteria, and shifting parental demographics such as older parental age. Genetic factors are recognized as primary contributors, with environmental influences under investigation.

Against this background, Kennedy’s research efforts have remained opaque, led by allies skeptical of vaccines and excluding input from mainstream autism advocacy groups and career scientists. The Interagency Autism Coordinating Committee was reconstituted with members including vaccine critics and others controversial for autism treatments, meeting only once this term.

Academic studies published in high-profile journals such as JAMA and JAMA Pediatrics have debunked assertions linking acetaminophen use during pregnancy, circumcision, or the hepatitis B vaccine with autism. Despite this, the administration has cut funding for established environmental autism research and directed $50 million in new grants focused on autism, with most projects years from completion.

What This Means

This decision to reduce childhood vaccinations risks undermining public trust in established immunization programs that have long prevented outbreaks of serious infectious diseases. It also diverts attention and funding from evidence-based autism research that examines genetic and environmental determinants of the condition. For families and healthcare providers, the enduring false association between vaccines and autism may increase vaccine hesitancy, complicating efforts to maintain herd immunity and protect vulnerable populations.

Politically, the timing highlights the tension between the administration’s desire to address autism concerns politically and the scientific community’s consensus rejecting vaccine causation. Kennedy’s isolated and secretive approach has alienated key stakeholders, thereby limiting progress in understanding autism and potentially delaying interventions that might improve the quality of life for autistic individuals and their families.

Background

Decades of research by the Centers for Disease Control and Prevention, World Health Organization, and multiple independent groups have found no credible evidence that vaccines cause autism. The rise in autism prevalence is widely regarded by scientists as a result of increased awareness, diagnostic changes, and demographic factors rather than vaccine exposure.

Nevertheless, skepticism and misinformation about vaccines persist in some political and social circles. Kennedy, sharing a history of vaccine criticism, has positioned autism as a “preventable disease,” a view contrasted sharply by mainstream medical experts. His efforts to reshape federal autism research priorities have been marked by controversy and stalled outcomes.

Analysis

Experts such as psychologist Helen Tager-Flusberg, director of the Coalition of Autism Scientists, criticize Kennedy’s research as the most secretive and opaque autism project in recent memory, likening it to a military-style operation lacking transparency. Officials familiar with the project describe a lack of engagement with the broader scientific and advocacy communities.

NIH Director Jay Bhattacharya acknowledged publicly on CBS that the cause of the rise in autism remains unknown, underscoring the scientific uncertainty and the premature nature of claims linking vaccines to the disorder. The administration’s contradictory stance, combined with politically motivated timelines, challenges thorough scientific inquiry.

What Remains Unclear

Despite substantial spending and high-profile attention on the issue, no new conclusions have emerged to clarify the causes behind autism prevalence increases. The exact direction and leadership of Kennedy’s research effort remain undisclosed. It is unknown whether reduced vaccination recommendations will align with international standards or how they will impact public health outcomes in the U.S.

What Comes Next

The HHS has pledged to examine all biologically plausible hypotheses surrounding autism but has not provided a timetable for definitive findings or changes to vaccine policy. Researchers funded by recent grants are expected to report results in several years. Meanwhile, the political and public discourse around vaccines and autism will likely continue to influence public health messaging and policy decisions.

Read more Health & Public Health stories on Goka World News.

The post Trump Orders Cuts in Childhood Vaccines Amid Unproven Autism Claims appeared first on Goka World News.

What Happened

A recent online survey of over 2,000 adults with chronic conditions found that 71% would likely participate in clinical trials if given the chance, yet two-thirds reported that their healthcare providers had never discussed clinical trial opportunities with them. Another study analyzing 2020 data revealed that only 9% of adults have ever been invited to take part in a clinical trial. Challenges such as trial location, eligibility, and costs frequently prevent willing participants from enrolling. Recognizing these barriers, the U.S. Department of Health and Human Services in June announced initiatives to streamline clinical research and reconsider regulations that currently limit sponsor reimbursement for participant expenses like travel and lodging. Additionally, nearly 200 patient advocacy and public health groups pushed for the Senate to pass the Clinical Trial Modernization Act, which would allow sponsors to cover medical and nonmedical costs for participants and protect their eligibility for income-based aid programs by excluding support from federal taxation.

Key Facts

Up to 86% of clinical trials fail to meet recruitment targets within the designated time frame. In a 2019 study covering 8,893 cancer patients, 55.6% lacked a suitable trial at their treatment site, while 21.5% did not meet eligibility criteria for available trials. Despite 86% of primary care physicians indicating a willingness to refer patients, only 37% had ever done so, often prompted by patient inquiry, lack of response to standard treatments, or disease progression. Clinical trials often require frequent visits for monitoring, which poses a significant barrier for those living far from trial centers. While trial sponsors cover direct trial-related medical costs, patients usually remain responsible for deductibles, copays, and out-of-network charges. Nonmedical expenses such as travel, lodging, childcare, and lost wages further discourage participation. Efforts to decentralize trials and allow remote participation are in early stages but hold promise for expanding access.

What This Means

The data highlight a critical gap between patient willingness to enroll in clinical trials and their actual participation, reflecting structural issues in the U.S. clinical research ecosystem. Many patients remain unaware of trials or unable to participate due to logistical or financial constraints, which limits the representativeness of trial populations and slows medical progress. For individuals with serious illnesses like cancer, clinical trials may offer their best treatment options. Yet without accessible trial sites or financial support, those patients face lower odds of enrollment and the associated benefits of cutting-edge care and close monitoring.

Improving clinical trial participation is therefore not only a matter of patient education but also requires systemic changes including better integration of trial options into routine care, expanded insurance coverage policies, and financial safeguards that mitigate incidental costs. The proposed Clinical Trial Modernization Act and related government initiatives signal growing recognition of these issues and may reduce disparities in who can participate. Greater patient inclusion can accelerate the development of new therapies while ensuring trial findings apply broadly across diverse populations.

Background

Clinical trials are essential for testing new drugs, devices, preventive measures, or diagnostics before approval by the Food and Drug Administration. Participant recruitment and retention shape trial success but often prove difficult due to eligibility restrictions, geographic proximity to trial sites, and burdens of frequent monitoring visits. Under the Affordable Care Act, commercial insurers generally cover routine care costs during clinical trials, but patients still incur copays and deductibles. Medicare and Medicaid cover similar costs, though restrictions on out-of-network benefits persist. These factors collectively create financial toxicity that can discourage participation. Patient advocates have long called for reforms to address these barriers, with renewed momentum from the Department of Health and Human Services in 2023.

Analysis

Alan Balch, executive board chair at the Patient Advocate Foundation, emphasizes that every interaction in clinical trials presents potential access challenges, from initial recruitment to participant retention. Mark Fleury of the American Cancer Society Cancer Action Network points out that clinical trials may offer the only hope for improved outcomes in deadly diseases, underscoring the importance of equitable trial access. Wendy Selig, CEO of WSCollaborative, notes that incidental costs and lack of awareness about financial assistance contribute heavily to low enrollment and urges patients to proactively seek support. Experts agree that increased decentralization of trials could alleviate geographic barriers, but widespread adoption remains a work in progress.

What Comes Next

The U.S. Department of Health and Human Services continues its efforts to revamp clinical trial regulations, particularly around compensation for participant expenses. Lawmakers are moving forward with the Clinical Trial Modernization Act, pending Senate approval. Health advocacy groups and institutional stakeholders are collaborating on strategies to broaden trial accessibility through technology-enabled decentralized models and enhanced patient education. Monitoring the implementation and impact of these measures will be critical in addressing longstanding barriers to trial participation.

Read more Health & Public Health stories on Goka World News.

The post Understanding Barriers to Clinical Trial Participation in the U.S. appeared first on Goka World News.